A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

NCT01156571 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

11145

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis
Percutaneous Coronary Intervention
Acute Coronary Syndrome

Interventions

DRUG: cangrelor P2Y12 (platelet) inhibitor
DRUG: Clopidogrel - 300 or 600 mg (study arm)
DRUG: Clopidogrel 600 mg post cangrelor

Sponsor

The Medicines Company